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Abstract: There is accumulating evidence that physical fitness influences the gut microbiome and as
a result, promotes health. Indeed, exercise-induced alterations in the gut microbiome can influence
health parameters crucial to athletic performance, specifically, immune function, lower susceptibility
to infection, inflammatory response and tissue repair. Consequently, maintenance of a healthy gut
microbiome is essential for an athlete’s health, training and performance. This review explores the
effect of exercise on the microbiome while also investigating the effect of probiotics on various potential
consequences associated with over-training in athletes, as well as their associated health benefits.
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1. A Brief Introduction to Exercise and the Microbiome
Our gut microbiome, an elusive and recently designated organ, is under ever greater scrutiny.
Uncovering the significance of the microbiome in human health and disease has become possible
with the advent of various genomic tools accompanied by improvements in culture-based approaches
(culture-omics). The gut contains a rich and diverse microbial ecosystem whose activities can influence
the health of the host [1]. More specifically the gut is home to trillions of microbial species [2] that
co-exist with human cells. The dominant microbial populations in the gut are bacteria from the
Bacteroidetes and Firmicutes phyla, followed by members of the phyla Actinobacteria, Proteobacteria
and Verrucomicrobia. The microbiome also consists of a fungal community, including species of
Candida and Saccharomyces [3], viruses (primarily bacteriophage) [4], as well as members from the
archaeal domain [2]. Despite the microbiome being stable in adults, certain factors can alter its structure,
including, diet, antibiotics, probiotics and indeed exercise/fitness (for review see [5,6]). The microbiome
appears to have an effect on most aspects of human health. In addition to a role for specific microbes,
or groups of microbes, the importance of microbial diversity has been recognized in many studies, with
a decreased diversity associated with a number of gastrointestinal (GIT) conditions such as Crohn’s
disease [7], certain cancers [8] and Type 1 diabetes [9]. An altered microbiome can affect energy
metabolism, immune function and oxidative stress, all of which are vital for athlete’s performance and
overall health (for review see [10]). A potential, non-medical, route to maintaining athlete’s health is
through probiotics. Probiotics are defined as live bacteria that, when ingested in adequate amounts,
confer a benefit to the host [11]. Although such health benefits have frequently been credited to specific
bacterial strains from the genera Bifidobacterium and Lactobacillus, the potential of next-generation
probiotic (NGP) candidates and designer probiotics is also being recognized.
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Although it is generally accepted that microbial diversity is an indicator of human health, this
hypothesis has been challenged recently by Shade, who postulated that “mechanisms maintaining or
changing microbial diversity are many and complex” and assumptions that an increased diversity is
better may oversimplify complex mechanisms of health and disease [12]. As previously stated, certain
factors including an individual’s lifestyle can alter the structure of the microbiome. It has been noted
across a number of studies that athletes have increased gut microbial diversity compared with more
sedentary controls [13–15]. Clarke et al. [14] demonstrated significant gut microbiome differences
between male professional elite rugby players and a cohort of non-athlete male controls. Notably,
the athletes had significantly higher gut microbial diversity accompanied by elevated levels of the
Akkermansia genus. A subsequent study of the same cohort [13] concluded that athletes had a higher
abundance of short-chain fatty acids (SCFA) metabolic pathways. In another instance, Petersen et al. [15],
investigated the gut microbiome of cyclists and concluded that 30 out of 33 cyclists also had an increased
abundance of Akkermansia. It was also observed that exercise regime is proportional to the abundance
of Prevotella, which in turn has been associated with increased branched-chain amino acid (BCAA)
pathways, important in muscle recovery. There was also an increase in Methanobrevibacter smithii within
the professional cyclist group compared to amateur cyclists, a microbe that utilises H2 in the colon
to make SCFA and Adenosine triphosphate (ATP) [15]. More recently, Cronin et al. investigated the
impact of exercise and/or whey protein supplementation over an eight-week period on a cohort of
sedentary adults. In this instance, the differences between the microbial communities of the three test
populations were more subtle, a fact that could be attributed to the shorter period over which time these
interventions took place relative to the potentially life-long practices of some athletes, i.e., microbial
architecture is not easily changed and it may take more time to notice significant impacts [16]. Recently,
Jang et al. compared the gut microbiome of bodybuilders, distance runners and controls (n = 45),
each of the groups were ingesting a different sport specific diet. The results show that bodybuilders
ingesting a high-protein and fat diet had increased relative abundance of Faecalibacterium, Sutterella,
Clostridium, Haemophilus and Eisenbergiella, but decreased abundances of Bifidobacteria, Parasutterella and
Eubacterium. The study also concluded that individuals practicing anaerobic sports show similar gut
microbiome patterns to bodybuilders [17]. A pioneering study by Scheiman et al. discovered that the
genus Veillonella was enriched in the gut microbiome of marathon runners, compared to non-runners.
Furthermore, using a mouse model they demonstrated that Veillonella atypica increased endurance,
reduced inflammatory cytokines, and converted lactate to acetate/propionate [18]. The present studies
suggest that exercise can alter the microbiome in a beneficial manner, where the alteration in the
composition of the microbiome can be associated with increased health parameters and thus possibly
affect athletic performance in a beneficial way. Reported gut microbiome changes/differences associated
with exercise and fitness are summarized in Table 1.
Whilst exercise confers numerous physiological effects on the host including mood regulation [19],
improving cardiovascular symptoms [20], alleviation of fatigue [21] and anti-inflammatory effects, a
healthy balance between training load and recovery needs to be maintained to prevent the condition
of overtraining occurring [22]. Studies in the past have observed the effect of overtraining on the
microbiome; Allen et al. concluded that voluntary and forced exercise altered the mice microbiome
in different ways. Of particular interest were the phyla Tenericutes and Proteobacteria, both elevated
in forced exercised mice, compared to mice that exercised voluntarily. Tenericutes spp. have been
linked to intestinal inflammation in human subjects and Proteobacteria bacteria are known for their
lipopolysaccharide production [23]. Similarly, Karl et al. observed that there was a large increase in
pathogenic taxa post-exercise in soldiers including, Peptostreptococcus, Staphylococcus, Peptoniphilus,
Acidaminococcus, and Fusobacterium and a decrease in more beneficial taxa Bacteroides, Faecalibacterium,
Collinsellaa and Roseburia. The authors postulated that the increase in more toxic species may possibly
explain the observation of increased intestinal permeability within the soldier cohort [24]. More recently,
Yuan et al. concluded that excessive exercise had a negative impact on microbial diversity in murine
models [25].
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Table 1. Studies of exercise and the microbiome.
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Various studies throughout the years have investigated overtraining and its effect on human
health particularly host immunity [26,27] and susceptibility to infection [22,28,29]. The potential side
effects of overtraining are illustrated in Figure 1. Furthermore, overtraining has been associated with
an increased incidence of mental illnesses in athletes [30–33] and oxidative stress [34,35], where studies
in animal models have shown the relationship between the microbiome and oxidative stress [36,37].
One of the most common side effects of overtraining is gut dysfunction and it has been frequently
noted in athletes [38,39]. Gastrointestinal (GIT) symptoms are frequently observed with athletes who
tend to travel for training or competition, purposes [40,41]. Antibiotics can be used to overcome
the GIT infections, however, certain complications may arise when using antibiotics. Firstly, studies
have shown that the microbiome takes about six weeks to resemble its original state post antibiotic
therapy [42], it increases possible tendon rupture [43] and can cause antibiotic associated diarrhea [44].
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The review aims to provide a panoramic view of what is currently known about probiotics and
their effect on gut microbiome of athletes. A recent systematic review by Moller et al. [45] has provided
an overview of the effects of traditional probiotics on physically active individuals and athletes, with a
particular focus on the clinical trials performed to date. Here we explore the relationship between
fitness and the gut microbiome focusing particularly on overtraining. We also explore the available
literature on how, possibly, probiotics can help to alleviate or prevent the different side effects of
overtraining. We also discuss next generation and designer probiotics, as well as the safety and toxicity
considerations associated with novel strains.
2. Traditional Probiotics
Traditionally, the majority of probiotic strains were representatives of the lactic acid bacteria
group (LAB) i.e., Bifidobacterium, Lactobacillus [46], however other bacterial and yeast strains are also
commonly used such as Escherichia coli and Saccharomyces respectively. Although probiotics have
existed for quite some time, it is only recently that their commercial potential has been realized, with
the market expected to exceed $67 billion by 2024 [47]. Probiotics can consist of one or a combination
of a few strains, either as capsules, powders or as a component of a food e.g., yoghurt [48]. One of
the main concerns relating to the probiotic market is that some strains do not have substantial proof
of efficacy. It is also important for consumers to be aware that the benefits of one probiotic strain
cannot be inferred to another [48,49]. Nonetheless, there is increasing evidence of the ability of specific
probiotics to, for example, modulate the immune system, impact on tight-junction proteins and inhibit
pathogen colonization; this list is not exhaustive, and the benefits of probiotics are strain-dependent.
Focusing on athletes as noted above, extreme exercise can be associated with undesirable symptoms
and specific probiotics can help to ease or prevent certain gastrointestinal disorders, help with the brief
immunosuppression period, and reduce susceptibility to infections. Ways in which existing and novel
probiotics could contribute to athlete health are provided in Table 2.
2.1. Escherichia Coli
Escherichia coli, is the most diversely studied prokaryotic model organism in science. E. coli
belongs to the Enterobacteriaceae, a large family of Gram-negative bacteria consisting of commensal
and pathogenic bacteria, E. coli is a facultative anaerobe, meaning it can either respire or ferment,
depending on the environment, which maximises its growth in the gut. E. coli Nissle 1917 (EcN)
possesses antagonistic properties against Salmonella, Yersinia, Shigella and Listeria [50]. A study by
Wehkamp found that EcN induces the production of defensin in epithelial cells [51]. Various studies
have also demonstrated that E. coli affects the intestinal epithelial barrier [52,53], additionally EcN can
be used for irritable bowel disorder [53], constipation (for review see [54]), and has pro-inflammatory
potential [55]. EcN has been shown to repair the gut barrier function in vitro [53] and in murine
models [52]. Henker et al, investigated whether EcN is an effective therapeutic agent against acute
diarrhea in infants and toddlers. The randomized double blind placebo controlled trial, including
113 subjects concluded that, EcN successfully reduced the duration and incidence of diarrhea compared
to placebo, and improved the general health of the subject [56].
EcN has shown great promise in mitigating effects of gut barrier dysfunction, diarrhea and
impairment immune system, experienced often with the condition of overtraining. In order to prove
its efficacy more research is needed, especially involving athlete cohorts.
2.2. Lactobacillus
Lactobacillus species are Gram-positive bacteria belonging to the lactic acid bacteria group,
capable of lactic acid fermentation metabolism. Lactobacilli are frequently resistant to bile salts; an
important probiotic trait as it allows for the probiotic to survive in the hostile acidic environment of
the gastrointestinal tract [57]. Lactobacilli are frequently found in various fermented foodstuffs, silage,
human gut and the vagina [49–58]. Lactobacilli are amongst the most widely used and characterized
Nutrients 2019, 11, 2270 5 of 23
probiotics to date. Various strains from the species: Lactobacillus rhamnosus, Lactobacillus plantarum and
Lactobacillus acidophillus have been considered important probiotics, each strain exhibiting individual
functions. A small selection of very many examples are provided here, Lactobacillus casei GG has been
found to shorten diarrheal distress in subjects suffering from viral gastroenteritis [59], Lactobacillus
johnsonii BFE 6128 and Lb. plantarum BFE 1685 have been shown to aid in modulating the immune
system by inducing the secretion of the cytokine IL-8 in vitro [60], Lb. rhamnosus 4B15 and Lactobacillus
gasseri 4M13 have been suggested to inhibit the expression of inflammatory cytokines at transcriptional
level in vitro thus showing anti-inflammatory potential [61]. Among the aforementioned benefits,
lactobacilli are capable of inhibiting enteric pathogens through the production of lactic acid, bacteriocins
and hydrogen peroxide [62]. It is worth to mention that lactobacilli are biofilm matrix formers, which
makes the bacteria more resistant to antibiotics, and could potentially allow for longevity of the bacteria
in the gut [63].
Most studies to date have investigated the potential impact of lactobacilli in either animal models
or non-active human populations and, as of today, little has been done in athletes. Cox et al investigated
whether Lb. fermentum VRI-003 had any effect on mucosal immunity in elite male distance runners.
They observed a significant decrease in the duration and severity of respiratory illness, and a two-fold
increase in interferon gamma (INF
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) [64]. Another study examined Lb. fermentum (PCC®) and
its effects on gastrointestinal and respiratory health in competitive cyclists. In this study West
and colleagues deduced that Lb. fermentum (PCC®) was successful in reducing the severity of
gastrointestinal symptoms in male cyclists, in addition, it significantly reduced (20%–60%) cytokine
imbalance caused by acute exercise. Moreover, the study also concluded that the severity and duration
of lower respiratory illness decreased in male cyclists but increased in female cyclists, taking the
probiotic compared to placebo [65]. It is also worth noting that a recent study by Shing et al, reported
that a multi-strain probiotic formulation consisting of Lb. acidophilus, Lb. rhamnosus, Lb. casei, Lb.
plantarum, Lb. fermentum, B. lactis, B. breve, B. bifidum and Streptococcus thermophilus increased run to
fatigue time in male runners, and showed small to moderate improvement in gut permeability [66].
Overtraining can result in a compromised immune system and gut barrier function; in particular
lactobacilli are capable of reducing the severity and duration of upper respiratory tract infections (URTI)
and gastrointestinal problems, as well as modulating the immune system and increasing performance
and thus a good candidate probiotic for athletes.
2.3. Bifidobacterium
Bifidobacteria are Gram-positive anaerobic bacteria from the phylum Actinobacteria.
Associated strains are typically among the first colonisers of the infant gut and contribute to the infants’
immune system maturation and the utilisation of certain dietary components [67]. They are generally
bile-acid resistant [68] and represent a large proportion of the bacterial microbiome obtained from
infant faecal samples, on average about 60%–91% present in breast fed infants, but proportions decrease
greatly later in life [69]. Numerous strains from the species: Bifidobacterium breve, Bifidobacterium longum,
Bifidobacterium bifidum exhibit probiotic properties, several examples are listed below. The Bifidobacteria
genus is represented by many different strains that have been assigned probiotic properties, shown here
is a small selection of strains, although many more have been noted in literature A mixture of B. breve,
B. longum and Bifidobacterium infantis has been associated with the treatment of antibiotic associated
diarrhea [70], while two Bifidobacterium strains: B. breve strain Yakult and B. bifidum strain Yakult
have been shown by in vitro studies to have a possible role in modulating the immune system [71].
Even though bifidobacteria are frequently used in probiotic preparations and many studies have
elucidated their benefits in vivo, little has been studied in athlete populations. West et al investigated
whether a single strain of a probiotic (B. animlais subsp. lactis BI-04) compared against a multi-strain
probiotic (Lb. acidophilus NCFM and B. animalis subsp. lactis BI-04) was effective in reducing the risk of
upper respiratory tract infection in physically active individuals. The study concluded that B. animalis
subsp. lactis BI-04 reduced the risk of upper respiratory illness by 27%. The multi-strain probiotic
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did not show a significant decrease in risk of URTI [72]. Another worthwhile study investigated a
multi-strain probiotic composed of B. bifidum, B. longum and Lb. gasseri and its effect on the duration
and incidence of infection in elite rugby players. The findings were that the multi-strain probiotic
formulation reduced both the incidence and duration of URTI and gastrointestinal symptoms [73].
In addition to the aforementioned studies, Jäger and colleagues concluded that a probiotic composed
of B. breve BR03 and S. thermophilus FP4 has a positive effect on the reduced performance and range of
motion followed by intense muscle damaging exercise [74]. More recently, Pugh et al. demonstrated
that a four week supplementation of Lb. acidophilus (CUL 60/ CUL 21), B. bifidum (CUL20) and B. animalis
subsp. Lactis (CUL34) successfully lowered the incidence and severity of GIT symptoms both during
training and a marathon race [75]. Bifidobacteria supplementation can positively help with the burden
of gastrointestinal distress found often in overtrained athletes.
2.4. Saccharomyces
Saccharomyces is another commonly used probiotic; it is a non-pathogenic yeast, and is one of the
most common fungal species found in the microbiome [3]. The gut mycobiome represents about 0.1%
of the total microbiome [76]. Saccharomyces boulardii is most widely used for the treatment of traveler’s
diarrhea [77]; it can prevent antibiotic-associated diarrhoea and treat recurrent Clostridium difficile
infections [78]. Additionally, research suggests that taking S. boulardii benefits irritable bowel syndrome
sufferers [79]. It is not to be overlooked that immunocompromised patients are at risk of fungemia,
if supplementing with Saccharomyces [78]. The effect of S. boulardii on diarhoea was elucidated by
Kurugol and Koturoglu, where they enrolled 200 young children in a randomized placebo study.
The study concluded that S. boulardii successfully reduced the duration of diarrhea and hospital stay
associated with it, compared to placebo [80]. In a similar study, Billoo et al. investigated S. boulardii
and its possible impact on diarrheal episodes in 100 children, the study concluded that the probiotic
reduced the number of diarrhea episodes by 50%, lowered stool frequency and the duration of the
illness [81].
It can be postulated that S. boulardii could possibly be an effective treatment for athletes and their
reoccurring gastrointestinal problems.
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Table 2. Traditional probiotics and next-generation probiotics and their benefits.
Probiotic Genus * Found in the Body Dietary Source: Potential Benefits Attributed to Specific Strains References
Lactobacillus Colon, gut and vagina Yoghurt, fermented foods,bread, sauerkraut, wine etc.
Gastroenteritis, easing lactose intolerance, immune system
modulation, alleviating inflammation, lowering cholesterol,
cancer protection, modulating brain activity, preventing
pathogen colonisation, bile resistant.
[60–62,68,82–87]
Bifidobacterium Colon, oral cavity, breast milkand vagina
Yoghurt, kombucha, sauerkraut,
kefir etc.
Bile resistant, easing lactose intolerance,
antibiotic-associated diarrhoea, eczema, immune system
modulation, cholesterol lowering abilities
[68,71,88–90]
Saccharomyces Colon, decaying fruit, plants,soil, insects
Wine, yoghurt, kombucha,
sauerkraut etc.
Travellers’ diarrhoea, antibiotic-associated diarrhoea,
preventing recurring Clostridium difficile infections, irritable
bowel syndrome
[77–79]
Escherichia coli Colon Capsules
Antagonistic properties against a variety of pathogens,
production of defensin, tight-junction protein modification,
irritable bowel disorder, constipation, pro-inflammatory
properties and colon cancer
[50–54,91]
Bacteroidetes Colon - Immune system modulation, intestinal homeostasis [92–94]
Akkermansia Colon - Gut barrier function, fat mass storage, glucose homeostasis,immune system stimulation, production of Vitamin B12 [95–101]
Faecalibacterium Colon - Immune system modulation, ease inflammation [102,103]
Eubacterium Colon -
Improve insulin sensitivity, increase energy production,
produce Vitamin B12, maintain intestinal homoestasis, colon
detoxification, reducing the symptoms of colitis
[104–107]
* Some of the mentioned genera are regarded as potential probiotics.
Nutrients 2019, 11, 2270 8 of 23
3. Next-Generation Probiotics
Next-generation probiotics still merit the definition of a probiotic and although they have
not been used as health modulators to date, have potential to be of importance to the probiotic
market. Next-generation probiotics are outside of the commonly used probiotic spectrum (Lactobacilli,
Bifidobacteria etc.), however large-scale genomic initiatives have identified putative probiotic strains
with potential health benefit, mainly from the genera Bacteroides, Akkermasia, Faecalibacterium and
Eubacterium.
One promising candidate is a strain of Bacteroides fragilis which has been proposed to stimulate
T-cell immune responses in vitro [108], this is of interest as athletes have decreased numbers of T cells
following intensive anaerobic exercise [109]. Similarly, strains of, Bacteroides acidifaciens have been
suggested to induce IgA production in murine models and as a consequence elevating the production
of IgA+ B cells and B cells; this is important because IgA plays a pivotal role in upholding intestinal
homeostasis namely preventing the adherence of pathogens in the intestine [94], studies in the past
have demonstrated the decrease in salivary IgA in endurance athletes [110,111] as well as when
decreased it has been linked to a higher incidence of URTI [112]. Studies have illustrated the potential
role of Akkermanisa in obesity, diabetes and inflammation (for review see [96]). Akkermansia muciniphilia
has been associated with maintaining gut barrier function, which can be compromised in endurance
athletes [113,114], and glucose homeostasis [97,98] and its direct correlation to athletic performance [115]
and additionally it has the potential to stimulate the immune system [97,99–101]. The most recent
study has concluded that A. muciniphilia is capable of synthesising Vitamin B12 de novo, however
whether humans can benefit from the product remains unclear [95]. Considering that recent studies
demonstrated an increase in Akkermansia in athletes this is a species that definitely warrants further
investigation for use in athletes [13–15]. Another potential probiotic is the Faecalibacterium prausnitzii.
F. prausnitzii A2-165 has been proposed to have immunodulatory capabilities, through induction of
IL-10 and T-cell responses in human and murine dendric cells [102,103,116]. Another worthy strain
belongs to the genus Eubacterium. Eubacterium hallii L2-7 has been demonstrated to improve insulin
sensitivity and increase energy metabolism in obese and diabetic murine models [104], E. hallii DMS
3353 and E. hallii DSM 17630 have been indicated to produce Vitamin B12 and maintain intestinal
homeostasis through the utilisation of glucose and various fermentation intermediates like acetate
and lactate in vitro studies [105], while, Eubacterium limosum JCM 6421 has been suggested to produce
SCFAs that have been shown to decrease the levels of the pro-inflammatory cytokine IL-6 and increase
mucosal integrity [107].
Preliminary research has shown the benefit of the various new generation probiotics however
more proof is required to ensure their efficacy, as well as testing for their safety in humans. The potential
benefits of next-generation probiotics are also summarized in Table 2.
4. Designer Probiotics
In recent years, research has uncovered numerous functions provided by probiotics, including
antagonistic activities, anti-inflammatory and tight-junction modification all of which are of particular
benefit to athlete health. Designer probiotics are simply commensal strains of bacteria that have been
engineered or modified in a way that they are able to resist the countless stresses that they meet
both outside and inside our bodies (lyophilisation/manufacturing/acids/temperature) or simply just to
improve the functions most beneficial to the host. The advent of synthetic biology has allowed for
engineering of both probiotic strains and commensal strains to acquire and execute new functions
(for review see [117]). The most recent concept in the probiotic field is the idea of a “biodrug”, which
essentially allows for oral administration of a live recombinant probiotic strain of bacteria for the
treatment/prevention of diseases. In the past 10 years, recombinant probiotics have been engineered,
for the delivery of therapeutic molecules (usually proteins, fragile in nature, easily denatured by
changes in the environment) such as DNA, peptides, single-chain variable fragments, various enzymes
or cytokines. Probiotics are excellent vectors of transmission for such therapeutics, due to; a) their
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ease of colonization and direct delivery to the mucosa; b) resistance to gastric acid and bile salts;
c) continued colonization and longevity of protection against pathogens; d) cost of delivery being
relatively non-expensive; e) prolonged shelf-life and stability (for review see [118]). Designer probiotics
could potentially be an attractive proposition to athletes due to their amenability to being tailored to
the athletes specific needs.
Lb. plantarum NC8 which has been engineered to possess angiotensin-converting enzyme inhibitory
peptides (ACEIPs), showed reduction of high blood pressure in rats [117]. It has also been shown that
engineering Lactococcus lactis NZ29000, B. longum and Lb. gasseri ATCC 33323, managed the symptoms
of diabetes and induced insulin secretion. More probiotics are currently under investigation for
pathogen infection, cancer or human immunodeficiency virus (HIV), however certain issues arise with
engineering probiotics [117]. Tackling the problem of biocontainment should be addressed to prevent
the spread of genetically modified microorganisms (GMO) organisms into the natural environment [118]
and, of course, the consumer acceptance of GMO products is still a major issue. With that being said,
designer probiotics are a great alternative to todays, often impermanent medication.
5. Safety Considerations
When a novel probiotic strain is being considered, evidence needs to be presented to prove its
efficacy and safety for human consumption. Even though probiotics are generally considered safe for
use, certain side effects may arise. In a statement released by the World Health Organisation (WHO) and
the Food and Agriculture Organisation of United Nations (FAO) in 2002, probiotics in theory can have
four possible side effects: 1) they can be responsible for lateral gene transfer of antibiotic resistant genes
i.e. Lactobacillus spp. 2) They can be responsible for systematic infections i.e. Fungemia. 3) They can
stimulate the immune system excessively due to their immune system modulation potential, possibly
causing inflammation; and 4) they are detrimental to metabolic activities, as some strains produce
D-lactate which can be linked to d-acidosis (for review see [119]). However, with the advent of whole
genome sequencing some of these issues can be identified or at least indicated using bioinformatics tools.
Genus, species and strain level need to be provided, the nomenclature must agree with the International
Committee of Systemics of Prokaryotes, and covered by the International Code of Nomenclature (ICN)
of Prokaryotes for bacteria, for fungi, the nomenclature is covered by the ICN for algae, fungi and
plants, the organism under consideration should be deposited in a recognized culture collection and
identified by the means of current methodologies such as whole-genome sequencing (WGS). As well as
using WGS to identify the organism, sequencing should be used to fully analyse the genetic content of
the probiotic (both chromosomal and extra-chromosomal) to determine the presence of any transferable
antimicrobial resistance loci, virulence factors or production of adverse metabolites that might deem the
strain unsafe for human consumption [120]. The European Food Safety Authority (EFSA) guidelines
also require full antimicrobial resistance (AMR) testing. AMR testing requires two sets of data, firstly
the phenotypic testing determining the minimum inhibitory concentration (MIC) of the antimicrobial,
using internationally recognized standards (ISO or similar), serial two-fold dilutions should be applied
using relevant controls. The results should be compared to established and published MIC cut off
values. Secondly, WGS is required to test for the presence of known AMR genes. Probiotic supplements
are sold in many different doses depending on the product and strain. Most commercially available
probiotics contain about 1–10 billion colony forming units (CFU) per serving. Generally, the CFU of
the product should be equivalent to human studies, showing a positive effect. As of now no strict
guidelines exist on the dosage of probiotics [121,122]. Consumers should also be aware that for the most
part multi-strain probiotics are more effective than monostrain preparations [123]. It is to be assumed
that, new probiotic strains with the intent of consumption, should be of human origin (although
Saccharamyces spp., is an exception), their safety, benefits, and dose ratio, should be clearly stated
and assessed (for review see [124]) Before the consumer purchases a probiotic it is recommended to
research the probiotic strain best suited for their needs paying particular attention to studies performed
in human subjects. Customers should ensure the commercial probiotic dosage is consistent with
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the dosage used in human studies. An important consideration to keep in mind is that the use of
probiotics in sport is still a novel area; therefore, most studies to date are preliminary pilot studies,
where the dosage and exact benefit of the strain are not fully optimized, and therefore should be
reasoned with caution.
6. Probiotics in Treating the Overtraining Syndrome
Overtraining can put the athlete at risk of developing asthma [125], infection such as upper
respiratory illness [126,127], gastrointestinal complaints [128] as well as depression and anxiety [129].
Various other symptoms such as immunity suppression and chronic fatigue are also very common [26].
The symptoms can have negative effects for the athlete; impeding progress and decreasing performance.
Various studies have explored the positive relationship between athletes and probiotics, and how
they can possibly be used to ease or prevent symptoms associated with overtraining. The effects of
probiotics on athletes and physically active individuals are summarized in Table 3.
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Table 3. Summary of studies using probiotics on physically active and athlete cohorts.
Subject Group Intervention Result Limitations of the Study References
20 male elite distance runners. Randomized
double-blinded, placebo controlled trial, Lb. fermentum VRI-003
↓ risk and severity of respiratory systems
↑ INF
Nutrients 2019, 11, x FOR PEER REVIEW 6 of 25 
 
depending on the environment, which maximises its growth in the gut. E. coli Nissle 1917 (EcN) 
possesses antagonistic properties against Salmonella, Yersinia, Shigella and Listeria [50]. A study by 
Wehkamp found that EcN induces the production of defensin in epithelial cells [51]. Various studies 
have also demonstrated that E. coli affects the intestinal epithelial barrier [52,53], additionally EcN 
can be used for irritable bowel disorder [53], constipation (for review see [54]), and has pro-
inflammatory potential [55]. EcN has been shown to repair the gut barrier function in vitro [53] and 
in murine models [52]. Henker et al, investigated whether EcN is an effective therapeutic agent 
against acute diarrhea in infants and toddlers. The randomized double blind placebo controlled trial, 
including 113 subjects concluded that, EcN successfully reduced the duration and incidence of 
diarrhea compared to placebo, and improved the general health of the subject [56].  
EcN has shown great promise in mitigating effects of gut barrier dysfunction, diarrhea and 
impairment immune system, experienced often with the condition of overtraining. In order to prove 
its efficacy more research is needed, especially involving athlete cohorts. 
2.2. Lactobacillus 
Lactobacillus species are Gram-positive bacteria belonging to the lactic acid bacteria group, 
capable of lactic acid fermentation metabolism. Lactobacilli are frequently resistant to bile salts; an 
important probiotic trait as it allows for the probiotic to survive in the hostile acidic environment of 
the gastrointestinal tract [57]. Lactobacilli are frequently found in various fermented foodstuffs, silage, 
human gut and the vagina [49–58]. Lactobacilli are amongst the most widely used and characterized 
probiotics to date. Various strains from the species:  Lactobacillus rhamnosus, Lactobacillus plantarum 
and Lactobacillus acidophillus have been considered important probiotics, each strain exhibiting 
individual functions. A small selection of very many examples are provided here, Lactobacillus casei 
GG has been found to shorten diarrheal distress in subjects suffering from viral gastroenteritis [59], 
Lactobacillus johnsonii BFE 6128 and Lb. plantarum BFE 1685 have been shown to aid in modulating the 
immune system by inducing the secretion of the cytokine IL-8 in vitro [60], Lb. rhamnosus 4B15 and 
Lactobacillus gasseri 4M13 have been suggested to inhibit the expression of inflammatory cytokines at 
transcriptional level in vitro thus showing anti-inflammatory potential [61]. Among the 
aforementioned benefits, lactobacilli are capable of inhibiting enteric pathogens through the 
production of lactic acid, bacteriocins and hydrogen peroxide [62]. It is worth to mention that 
lactobacilli are biofilm matrix formers, which makes the bacteria more resistant to antibiotics, and 
could potentially allow for longevity of the bacteria in the gut [63]. 
Most studies to date have investigated the potential impact of lactobacilli in either animal models 
or non-active human populations and, as of today, little has been done in athletes. Cox et al 
investigated whether Lb. fermentum VRI-003 had any effect on mucosal immunity in elite m le 
distance runners. They observed a significant decr ase in th  duration and everity of respiratory 
illness, and a two-fold increase in interferon gamma (INF ƴ ) [64]. Another study examined Lb. 
fermentum (PCC®) and its effects on gastrointestinal and respiratory health in competitive cyclists. In 
this study West and colleagues deduced that Lb. fermentum (PCC®) was successful in reducing the 
severity of gastrointestinal symptoms in male cyclists, in addition, it significantly reduced (20%–60%) 
cytokine imbalance caused by acute exercise. Moreover, the study also concluded that the severity 
and duration of lower respiratory illness decreased in male cyclists but increased in female cyclists, 
taking the probiotic compared to placebo [65]. It is also worth noting that a recent study by Shing et 
al, reported that a multi-strain probiotic formulation consisting of Lb. acidophilus, Lb. rhamnosus, Lb. 
casei, Lb. plantarum, Lb. fermentum, B. lactis, B. breve, B. bifidum and Streptococcus thermophilus increased 
run to fatigue time in male runners, and showed small to moderate improvement in gut permeability 
[66]. Overtraining can result in a compromised immune system and gut barrier function; in particular 
lactobacilli are capable of reducing the severity and duration of upper respiratory tract infections 
(URTI) and gastrointestinal problems, as well as modulating the immune system and increasing 
performance and thus a good candidate probiotic for athletes. 
2.3. Bifidobacterium 
A small sample size [64]
99 male and female competitive cyclists.
Randomized, double-blinded, placebo trial Lb. fermentum (PCC
®)
↓ severity of GIT symptoms
↓ severity/duration of lo er
respiratory illness
↓ cytokine imbalance
Inclusion criteria for antibiotics was only four
weeks, study reli d on self-reported illness,




Randomized, double-blinded, placebo trial
Lb. acidophilus, Lb. rhamnosus, Lb. casei, Lb.
plantarum, Lb. fermentum, B. lactis, B. breve,
B.bifidum and Streptococcus therm philus
↑ increased run time to fatigue,
small to moderate improvement in
gut permeability
Study only investigated males, sample size was
too small, short study duration of 4 weeks. [66]
465 physically active males and females.
Randomized double blind placebo
controlled trial
B. animalis subsp. lactis BI-04 (BI-04), Lb.
acidophilus NCFM and B.animalis subsp.
lactis BI-04 (NCFM and BI-04)
↓ the risk of URTIs by 27%
No separation between recreational and
professional athletes, study relied on self-reported
illness data, inclusion criteria for antibiotic use was
only four weeks.
[72]
30 male elite male rugby players.
Randomized, double-blinded,
Placebo trial.
B. bifidum B. longum Lb. gasseri ↓ in the incidence of URTI/GIT
Relatively small sample size, study only looked at
males, short study duration of 4 weeks, relied on




Randomized, double-blinded, placebo trial. B. breve BR03 and S. thermophilus FP4
positive effect on the reduced
performance and range of motion
followed by intense muscle damaging
exercise
Small sample size, looked at males only, didn’t
include antibiotic use in inclusion criteria, short
study duration of 3 weeks
[74]
24 amateur athletes
Lb. acidophilus (CUL60/CUL21), B. bifidum
(CUL20), B. animalis subsp. Lactis
(CUL34)
↓ incidence and severity of GIT
symptoms, both during training and a
marathon race
Small sample size, ratio of males to females was
skewed, athletic levels weren’t standardized, not
double-blinded.
[75]
24 amateur male athletes Lb. rhamnosus IMC 501 and Lb. paracaseiIMC 502 ↓antioxidant levels followed by exercise
Small sample size, short study duration of 4 weeks,
studied males only, study did not include placebo
in control group
[130]







Small sample size, only looked at men, looked at
only one marker or impaired
intestinal permeability
[131]
27 trained amateur athletes Lb. acidophilus LAFTI® ↓fatigue
Small sample size, sample size of control group
was significantly lower than test group, the ratio of
male to females was skewed, not randomized or
double blinded.
[132]
44 university student athletes.
Randomized, double-blind, placebo
controlled trial.
Lb. gasseri OLL2809 combined with
alpha-lactalbumin
prevents the exercise induced drops in
Natural Killer cells
positive effect on minor fatigue
↑mood from a depressive state
Study only looked at males, all participants were
at a university level, relied on self-reported illness,
short study duration of 4 weeks
[133]




B. W51, Enterococcus faecium W54, Lb.
acidophilus W22, Lb. brevis
W63, and Lactococcus lactis W58
↓drops of tryptophan levels caused by
intense exercise
↓incidence of URTI’s
Relatively small sample size, women were
overrepresented; the severity of illness could not
be calculated due to lack of replies
from participants.
[134]
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6.1. Antioxidant Boosting
Oxidative stress is the imbalance between oxidant and antioxidant levels in the body; it results in
the creation of reactive oxygen species (ROS). Our bodies counteract them with special enzymes that
neutralize the reactive species and if the species are not neutralized then they can compromise the
cell [135]. Diseases such as rheumatoid arthritis, heart disease, Parkinson’s disease and aging can all
be linked to oxidative stress. Intense physical regime coupled to the increased oxygen consumptions
results in athletes having a higher abundance of reactive oxygen species [130]. Various probiotic species
have been reported to have antioxidant activities; Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus
delbrueckii ssp. lactis, Lb. acidophilus, Lb. casei [136]. Studies have also demonstrated the antioxidant
activity of B. animalis, which was found to absorb hydroxyl radicals and superoxidase anions in vivo,
as well as, increasing the general antioxidase activity in murine species [135]. Certain probiotic strains
have also been found to manufacture metabolites that have antioxidant abilities such as; Lb. fermentum
E3 and E18 have been found to produce glutathionine (GSH), and Clostridium butyricum has been
detected to produce the SCFA butyrate [135]. SCFAs have health-aiding properties and are thought
to help with the immune system [137,138] as well as insulin resistance [139]. Martarelli et al has
investigated if two probiotic strains (Lb. rhamnosus IMC 501 and Lb. paracasei IMC 502) have any effect
on the oxidative stress of athletes during a four-week time frame of intense training [130]. The study
came to two findings; firstly, intense exercise significantly increased the oxidative stress in athletes, and
secondly, the probiotic course successfully lowered the oxidative stress caused by the intense exercise.
6.2. Tight-Junction Protein Modification
The mucosal layer of the intestine is made up of several constituents namely; enterocytes
and epithelial cells, which are interconnected by tight junctions. This intestinal barrier is pivotal in
nutrient and water absorption, while preventing harmful substances entering the bloodstream [140,141].
During intense continuous exercise, cardiovascular and thermoregulatory responses augment the blood
flow, increasing the phosphorylation state of the tight-junction proteins consequently increasing their
permeability (Figure 2). Increased permeability can cause; vulnerability to allergies and infections, along
with various gastrointestinal complaints [142]. A randomized, double-blinded, placebo-controlled
trial has investigated two probiotic brands in relation to markers of intestinal barrier integrity on
23 endurance male athletes. The probiotics of choice were Ecologic®Performance (B. bifidum W23,
B. lactis W51, Enterococcus faecium W54, Lb. acidophilus W22, Lb. brevis W63, L. lactis W58) and
OMNi-BiOTiC®POWER (E. faecium W54, Lb. acidophilus W22, Lb. brevis W63, L. lactis W58, B. bifidum
W23, B. lactis W51). The study investigated the concentration of Zonulin in faeces, a marker of
impaired gut barrier. The study concluded that the probiotic treatment effectively decreased Zonulin
concentrations in faeces from above normal to below normal, during the 14 days of the study, when
compared to a placebo [142].
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6.3. Immune System Modulation
It has been documented that overtraining can lead to immunosuppression within the
individual [26]. The tissue trauma associated with excessive training results in overproduction
of cytokines (IL6, TNF-alpha) which subsequently lead to chronic fatigue-like behaviour in athletes,
followed by the induction of a humoral response, resulting in the suppression of cell-mediated
immunity resulting in a higher chance of infections (for review see [143]).
Much research has focused on potential probiotics and their strain specific effect on the immune
system. Throughout the years several different probiotics have been found to influence the host
immune system. Studies have shown that Lb. plantarum 299v is capable of inducing mucin, MUC2 and
MUC3, which is important in hindering pathogen colonization [144,145]. Mucin is a large glycosylated
protein which protects the intestines by a minimum of three mechanisms: a) it creates a gel-like
structure to trap various molecules; and b) it can bind to various molecules, pathogens or proteins
through very specific binding sites and c) through disposal of trapped organisms or proteins [146].
Escherichia coli have also been assigned some immunomodulatory functions in recent years, EcN
has been found to induce beta-defensins, defensins are s all peptides which are the innate immune
systems first line of defence, they are produced by epithelial cells of the intestinal tract, skin and lung.
Defensins have a broad antagonistic spectrum against various pathogens and are active against both
Gram-positive and negative bacteria as well as fungi [147]. A cheese product containing live a culture
of Lb. rhamnosus HN001 and Lb. acidophillus NCFM has been proven to improve the ability of natural
killer cells (NK Cells) to kill cancerous cells and phagocytosis in elderly subjects. Clancy et al. [132]
investigated if a daily dose of Lb. acidophilus could reverse a defect in INF-y secretion in fatigued
athletes. The study has concluded that treatment with Lb. acidophillus has significantly increased
IFN-y secretion in fatigued athletes to comparable levels of the control cohort. Another worthy study
has investigated the effect of probiotic supplementation on respiratory infections and gastrointestinal
symptoms of 141 marathon runners. The probiotic of choice was Lb. rhamnosus GG, compared with a
placebo pill. The findings of the study were as follows: there was no significant improvement in the
URTI, however, Lb. rhamnosus GG decreased the duration of the gastrointestinal symptoms by 33%
during the training period, compared to the placebo [148]. Various studies have elucidated immune
modulation induced by Akkermansia. A study by Derrien et al. determined that A. muciniphilia is
capable of up regulating genes involved in antigen presentation, as well as aiding in B and T cell
maturation [100]. Ottman also investigated A. muciniphilia and its immune modulation activity, and
concluded that Akkermansia could activate Toll like receptor 2 (TLR) and TLR4 and induce IL8 and
IL10 [101].
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6.4. Infection
Overtraining can lower the immune system and in turn result in an “open window” period,
where sensitivity to infection is increased [126,149]. Athletes are vulnerable to GI, URTI, and skin
infections [150].
To benefit the residential flora, probiotic strains need to show antagonistic activities against
pathogens. There are two types of antimicrobials produced by certain probiotic strains: high molecular
weight compounds called bacteriocins, and low molecular weight compounds including, but not
restricted to: hydrogen peroxide, lactic acid, acetic acid and reuterin [151]. Lactic acid, acetic acid
and hydrogen peroxide are the most common antimicrobial compounds secreted by probiotic species.
LMW compound production is specific to its species, and the effectiveness of microbial inhibition is
directly proportional to the amount of organic acid produced [152]. Bacteriocins are small peptides
that have been ribosomally-synthesized which possess antagonistic properties against other bacteria,
to which the producing strain is immune (for review see [153]). Bacteriocins can either be narrow
spectrum (bactericidal against closely related bacteria) or broad spectrum (bactericidal against a wide
variety of strains (for review see [151,154]). They can be classified into three groups, Class 1 bacteriocins
are lantibiotics which possess lanthionine or beta-metyllanthionine residues, like nisin, Class 2 can
be classified as non-lanthionine containing bacteriocins such as lactacin F, and finally bacteriolysins
which are non-bacteriocin lytic proteins like lysostaphin [153]. Bacteriocins are an important trait
for a probiotic to possess, they can aid in the survival of the producer within a gut [155], help
inhibit the proliferation of other bacteria and function as sensing molecules (for review see [155,156]).
The production of bacteriocins is dependent on a variety of factors including, the bacterial species
producing the antimicrobial compound, and the environmental conditions present. Different bacteria
produce various types of bacteriocins, for example, Lb. reuteri is known to produce reuterin, L. lactis
produces Nisin A, E. faecalis DS16 makes Cytolisin, Lb. plantarum manufactures Plantaricin S and
Lb. acidophillus makes acidophilicin. The production of antimicrobial entities is an important probiotic
trait. It allows for longer survival of the producer in the intestine, as well as having the potential to
outcompete pathogenic bacteria maintaining a healthy bacterial balance in the gut. Athletes tend to
be prone to gastroenteritis and other infections, and the antimicrobial compounds produced by the
probiotics can help in easing or preventing the symptoms.
6.5. Mental Health
The ubiquity of depressive symptoms in elite athletes ranges from 4%–68%, with the consensus
that female athletes are more likely to develop depressive episodes than male athletes. Athletes, who
take part in individual sports, rather than team-based sports, tend to be more susceptible to depressive
symptoms. Elite athletes face risk factors that contribute to depression including, genetic factors,
environmental factors, injury, competitive failure, retirement from sport, pain, concussion and of
course overtraining [157].
A study by Sashihara [133] and colleges investigated if Lb. gasseri OLL2809 combined with
alpha-lactalbumin decreases symptoms of depression. The study has found that Lb. gasseri OLL2809 has
successfully elevated symptoms of depression in college athletes. Similarly, Strasser et al. investigated
the effect of a multi-species probiotic formulation (B. bifidum W23, B. lactis W51, E. faecium W54, Lb.
acidophilus W22, Lb. brevis W63, L. lactis W58) and its possible effect on tryptophan levels, often
implicated in the etiology of depression [158]. The study concluded that the multispecies probiotic
formulation had a positive effect on the tryptophan-kynurenine pathway by successfully reducing the
exercise-induced depletion of tryptophan levels that occur after excessive exercise [134].
7. Conclusion and Future Prospects
In conclusion, the relationship between physical fitness and the microbiome is a complex one.
Exercise and physical fitness can positively alter the composition of the microbiome and benefit host
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health, consequently maintaining athletic potential. Studies suggest that different forms of exercise
may influence the abundance of different bacterial populations and, hence, alter the microbiome
in a different way and, therefore, studies in the future should consider this. As addressed in this
review, strenuous exercise can put an athlete in a predicament where they are more prone to infection,
inflammation, depression and gut permeability dysfunction. Probiotics offer an effective strategy to
prevent or improve those symptoms and allow for continued athletic success without the drawback
of the aforementioned symptoms. Future research should aim to clarify the optimal dosage for each
individual strain with proven efficacy, as well as establishing whether the probiotic strains colonize
our intestine or are simply transient microorganisms with beneficial effects. The impact of probiotics
on the athletic population is a new and exciting area, where a limited amount of research has been
conducted to date, and although research has shown great promise, little is known about the benefits
of probiotics in highly active individuals and ultimately if they benefit from them.
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